Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of Tumor-Agnostic MRD Detection in Stage III Colorectal Cancer
Sponsor: Sun Yat-sen University
Summary
This observational study aims to evaluate the predictive performance of various omics-based methods for detecting minimal residual disease (MRD) in stage III colorectal cancer. The study involves the collection of blood samples from patients who have accepted surgery for colorectal cancer. Blood samples will be analyzed using both tumor-informed and tumor-agnostic approaches to detect circulating tumor DNA (ctDNA). The study will compare the sensitivity of these methods and assess their correlation with recurrence risk. The findings aim to inform the development of optimal MRD detection strategies, ultimately providing a robust molecular basis for personalized treatment decisions.
Official title: A Prospective, Multicenter, Exploratory Clinical Study Evaluating the Application of Tissue-Agnostic Technology in the Dynamic Monitoring of Minimal Residual Disease in Stage III Colorectal Cancer
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
229
Start Date
2025-11-24
Completion Date
2028-12-31
Last Updated
2025-11-28
Healthy Volunteers
No
Conditions
Interventions
MRD detection
Baseline blood samples, surgical resected tumor tissue, blood samples after surgery, and blood samples after adjuvant therapy will be collected from colorectal patients. MRD will be assessed using both tumor-informed and tumor-agnostic methods.
Locations (1)
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China